Aptose Biosciences Files Proxy Materials
Ticker: APTOF · Form: DEFA14A · Filed: Aug 1, 2025 · CIK: 882361
Sentiment: neutral
Topics: proxy-filing, regulatory, company-history
Related Tickers: APTO
TL;DR
APTO proxy filing out - standard stuff, check for shareholder votes.
AI Summary
Aptose Biosciences Inc. is filing a Definitive Additional Materials proxy statement on August 1, 2025. This filing relates to the company's proxy statement under Section 14(a) of the Securities Exchange Act of 1934. The company was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.
Why It Matters
This filing is a routine regulatory submission that provides shareholders with information relevant to upcoming corporate decisions or meetings, ensuring transparency and compliance.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEFA14A) and does not contain new material financial information or strategic changes that would inherently increase risk.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- Lorus Therapeutics Inc. (company) — Former company name
- Imutec Pharma Inc (company) — Former company name
- 0001171843-25-004949 (filing_id) — Accession Number
FAQ
What type of filing is this?
This is a Definitive Additional Materials proxy statement (DEFA14A) filed by Aptose Biosciences Inc.
When was this filing submitted?
The filing was submitted on August 1, 2025.
What is the company's primary business classification?
The company's Standard Industrial Classification is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
What are some of Aptose Biosciences Inc.'s former names?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.
What is the company's business address?
The business address is 66 Wellington Street West, Suite 5300, TD Bank Tower Box 48, Toronto, A6, M5K 1E6.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on August 1, 2025 regarding Aptose Biosciences Inc. (APTOF).